• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "January, 2023"
 Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
0
By Nascent Biotech
In Uncategorized
Posted January 25, 2023

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 NBIO Fits Profile for Strategy Targeting Early Stage Biotech
0
By Nascent Biotech
In Corporate News
Posted January 18, 2023

NBIO Fits Profile for Strategy Targeting Early Stage Biotech

One candidate that checks all of these boxes is Nascent Biotech Inc. (OTCMKTS:NBIO). NBIO checks all the boxes discussed above. It’s a dirt-cheap stock, trading on a market cap of just $16 [...]

READ MORE
 Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
0
By Nascent Biotech
In News, Press Releases, Science News
Posted January 10, 2023

Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial

NORTH PALM BEACH, FL / ACCESSWIRE / January 10, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.